These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 38278323)
1. Managing dyslipidaemia in patients with chronic kidney disease. Mehta A Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S90-S92. PubMed ID: 38278323 [TBL] [Abstract][Full Text] [Related]
2. A Clinical Guide to Combination Lipid-Lowering Therapy. Russell C; Sheth S; Jacoby D Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190 [TBL] [Abstract][Full Text] [Related]
3. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD). Shaik A; Kosiborod M; de Lemos JA; Gao Q; Mues KE; Alam S; Bhatt DL; Cannon CP; Ballantyne CM; Rosenson RS; Clin Cardiol; 2022 Dec; 45(12):1303-1310. PubMed ID: 36124341 [TBL] [Abstract][Full Text] [Related]
4. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240 [TBL] [Abstract][Full Text] [Related]
5. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492 [TBL] [Abstract][Full Text] [Related]
6. Nonstatin therapies for management of dyslipidemia: a review. Sando KR; Knight M Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799 [TBL] [Abstract][Full Text] [Related]
8. Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Puri R; Mehta V; Iyengar SS; Srivastava P; Yusuf J; Pradhan A; Pandian JD; Sharma VK; Renjen PN; Muruganathan A; Krishnan M; Srinivasan AV; Shetty S; Narasingan SN; Nair DR; Bansal M; Prabhakar D; Varma M; Paliwal VK; Kapoor A; Mukhopadhyay S; Mehrotra R; Patanwala RM; Aggarwal R; Mahajan K; Kumar S; Bardoloi N; Pareek KK; Manoria PC; Pancholia AK; Nanda R; Wong ND; Duell PB Curr Vasc Pharmacol; 2022; 20(2):134-155. PubMed ID: 34751121 [TBL] [Abstract][Full Text] [Related]
9. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N BMJ; 2022 May; 377():e069066. PubMed ID: 35508320 [TBL] [Abstract][Full Text] [Related]
10. Dyslipidemia in diabetes. Kalra S; Raizada N Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S80-S82. PubMed ID: 37956957 [TBL] [Abstract][Full Text] [Related]
11. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy? Cervelli N; Tocci G; Ferri C High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812 [No Abstract] [Full Text] [Related]
12. Pharmacotherapeutics for dyslipidemia management. El Hussein MT; Sharma A; Parmar K; Shelat K Nurse Pract; 2023 Jun; 48(6):36-47. PubMed ID: 37227314 [TBL] [Abstract][Full Text] [Related]
13. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335 [TBL] [Abstract][Full Text] [Related]
14. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377 [TBL] [Abstract][Full Text] [Related]
15. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. Chang Y; Eom S; Kim M; Song TJ Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109734 [TBL] [Abstract][Full Text] [Related]
16. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086 [TBL] [Abstract][Full Text] [Related]
17. [Ezetimibe as a treatment for dyslipidaemia in CKD]. Żebrowski P; Kaszyńska M Wiad Lek; 2019; 72(11 cz 2):2210-2213. PubMed ID: 31860838 [TBL] [Abstract][Full Text] [Related]
18. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. Lee S; Cannon CP Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475 [TBL] [Abstract][Full Text] [Related]
19. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
20. [Hypercholesterolemia and cardiovascular risk]. Sinning D; Landmesser U Dtsch Med Wochenschr; 2023 Aug; 148(16):1025-1032. PubMed ID: 37541292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]